Vericel VCEL
NASDAQ VCEL
$38.99 -0.09 (-0.23%)
As of: Sep 9, 2026 · 3:59 PM EDT

Vericel (VCEL) Preferred Stock Liabilities (2012 - 2013)

Vericel's (VCEL) quarterly Preferred Stock Liabilities came in at $42.9 million in Q2 2013, up 13.76% year-over-year from $37.7 million in Q2 2012, and little changed quarter-over-quarter from $42.9 million in Q1 2013.

Analysis

Vericel (VCEL) Preferred Stock Liabilities (2012 - 2013) Analysis & Trends

Vericel has disclosed Preferred Stock Liabilities across 2 years of filings, most recently posting $42.9 million for Q2 2013.

  • In Q2 2013, Preferred Stock Liabilities rose 13.76% year-over-year to $42.9 million; the TTM figure through Jun 2013 stood at $42.9 million (up 13.76% YoY), while the FY2012 annual figure was $41.6 million, changed N/A from the prior year.
  • Preferred Stock Liabilities came in at $42.9 million for Q2 2013 at Vericel, roughly flat from $42.9 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $42.9 million in Q1 2013 to a low of $37.7 million in Q2 2012.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Krystal Biotech 10.27 Bn 9.43 Bn 112.79 Mn -
2 CRISPR Therapeutics AG 5.17 Bn 5.17 Bn - -
3 Iovance Biotherapeutics 3.79 Bn 3.49 Bn 55.72 Mn -
4 Legend Biotech 3.68 Bn 2.71 Bn 251.50 Mn -
5 uniQure 3.05 Bn 3.05 Bn 5.49 Mn -
6 Beam Therapeutics 2.65 Bn 2.65 Bn - -
7 Precigen 2.44 Bn 2.44 Bn 52.17 Mn -
8 Sarepta Therapeutics 2.33 Bn 1.53 Bn 251.87 Mn -
9 Vericel 1.99 Bn 1.83 Bn 56.40 Mn -
10 Taysha Gene Therapies 1.97 Bn 1.97 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2013 42.88 Mn
Mar 31, 2013 42.88 Mn
Dec 31, 2012 41.61 Mn
Sep 30, 2012 40.36 Mn
Jun 30, 2012 37.69 Mn